众生药业(002317.SZ)控股子公司一类创新药ZSP1601片Ⅱb期临床试验完成首例受试者入组

智通财经2023-06-04

智通财经APP讯，众生药业(002317.SZ)公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)组织开展的用于治疗非酒精性脂肪性肝炎(NASH)的一类创新药物ZSP1601片Ⅱb期临床试验完成首例受试者入组。据悉，ZSP1601片适应症为治疗非酒精性脂肪性肝炎。ZSP1601片Ⅱb期临床试验为多中心、随机、双盲、安慰剂平行对照试验，评价ZSP1601片治疗非酒精性脂肪性肝炎的安全性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2340055967?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-06-04 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2340055967","market":"hk","top_or_hot":-1,"title":"众生药业(002317.SZ)控股子公司一类创新药ZSP1601片Ⅱb期临床试验完成首例受试者入组","media":"智通财经","content":"<div>\n<p>智通财经APP讯，众生药业(002317.SZ)公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)组织开展的用于治疗非酒精性脂肪性肝炎(NASH)的一类创新药物ZSP1601片Ⅱb期临床试验完成首例受试者入组。据悉，ZSP1601片适应症为治疗非酒精性脂肪性肝炎。ZSP1601片Ⅱb期临床试验为多中心、随机、双盲、安慰剂平行对照试验，评价ZSP1601片治疗非酒精性脂肪性肝炎的安全性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/940304.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>众生药业(002317.SZ)控股子公司一类创新药ZSP1601片Ⅱb期临床试验完成首例受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n众生药业(002317.SZ)控股子公司一类创新药ZSP1601片Ⅱb期临床试验完成首例受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-04 17:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/940304.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，众生药业(002317.SZ)公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)组织开展的用于治疗非酒精性脂肪性肝炎(NASH)的一类创新药物ZSP1601片Ⅱb期临床试验完成首例受试者入组。据悉，ZSP1601片适应症为治疗非酒精性脂肪性肝炎。ZSP1601片Ⅱb期临床试验为多中心、随机、双盲、安慰剂平行对照试验，评价ZSP1601片治疗非酒精性脂肪性肝炎的安全性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/940304.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/940304.html","article_id":"2340055967","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2340055967","pubTimestamp":1685872050,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，众生药业(002317.SZ)公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)组织开展的用于治疗非酒精性脂肪性肝炎(NASH)的一类创新药物ZSP1601片Ⅱb期临床","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK1576":"医药外包概念","06978":"永泰生物-B","BK1574":"生物医药B类股","BK0188":"融资融券","03347":"泰格医药","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","002317":"众生药业","BK0239":"医药制造","BK0077":"质押式回购","BK1161":"生物科技"},"translate_title":"Phase II B clinical trial of ZSP1601 tablets, a class of innovative drugs controlled by Zhongsheng Pharmaceutical (002317. SZ), completed the first subject's entry into the group","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"002317":1,"03347":1,"06978":1},"content_text":"智通财经APP讯，众生药业(002317.SZ)公告，公司控股子公司广东众生睿创生物科技有限公司(“众生睿创”)组织开展的用于治疗非酒精性脂肪性肝炎(NASH)的一类创新药物ZSP1601片Ⅱb期临床试验完成首例受试者入组。据悉，ZSP1601片适应症为治疗非酒精性脂肪性肝炎。ZSP1601片Ⅱb期临床试验为多中心、随机、双盲、安慰剂平行对照试验，评价ZSP1601片治疗非酒精性脂肪性肝炎的安全性和有效性，由全国知名肝病专家南方医科大学南方医院侯金林教授和吉林大学第一医院牛俊奇教授作为共同主要研究者，组织全国30多家临床研究中心参研。研究对NASH病理学确诊的受试者按照糖尿病状态进行分层随机化分组，以1:1:1的比例分配至ZSP1601片50mg组、ZSP1601片100mg组和安慰剂组，每组60例，给药观察48周。主要疗效终点为治疗48周后肝活检组织学显示NASH改善且纤维化无恶化，或纤维化改善1分及以上且NASH无恶化的受试者比例。基于ZSP1601片获得积极的Ib/Ⅱa期临床试验结果，众生睿创按药物临床试验相关要求组织开展Ⅱb期临床试验，并获得组长单位南方医科大学南方医院医学伦理委员会的同意，已于近日完成Ⅱb期首例受试者入组。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2340055967"}